Pegasus Partners’s Ocular Therapeutix OCUL Stock Holding History

Pegasus Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,000	Closed	-$112K	–	156
2023 Q4	$112K	Buy	+25,000	New	+$73.9K	0.01%	141

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pegasus Partners's OCUL Position: Q1 2024 in Review

Pegasus Partners sold out of Ocular Therapeutix (OCUL) in Q1 2024, closing a stake of 25,000 shares — an estimated $112K sold.

Pegasus Partners first reported a position in OCUL in Q4 2023 and held it in 1 quarter. The position peaked at $112K in Q4 2023. 148 funds tracked by Wall St. Rank hold OCUL as of Q1 2024.

Pegasus Partners reported no remaining Ocular Therapeutix position as of Q1 2024 after selling out during the quarter.
Pegasus Partners sold 25,000 Ocular Therapeutix shares in Q1 2024, an estimated $112K.
Pegasus Partners first reported a position in Ocular Therapeutix in Q4 2023 and held it in 1 quarter.
Pegasus Partners's Ocular Therapeutix position peaked at $112K in Q4 2023.
148 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2024.

Based on Pegasus Partners's 13F filing for Q1 2024, filed 24 Apr 2024.